Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

Author： Knudsen L.B.   Pridal L.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.318, Iss.2, 1996-12, pp. : 429-435

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucagon and Glucagon-Like Peptide Receptors as Drug Targets

By  

Current Pharmaceutical Design, Vol. 12, Iss. 14, 2006-05 ,pp. : 1731-1750

Bentham Science Publishers

Access to resources Recommend Favorite

The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease

By Hornby Pamela J   Moore Beverley A  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 5, 2011-05 ,pp. : 637-646

Informa Healthcare

Access to resources Recommend Favorite

Renal effects of glucagon-like peptide in rats

By Moreno C.   Mistry M.   Roman R.J.  

European Journal of Pharmacology, Vol. 434, Iss. 3, 2002-01 ,pp. : 163-167

Elsevier

Access to resources Recommend Favorite

Cardiovascular Effects of Glucagon-Like Peptide 1

By  

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 1, 2011-01 ,pp. : 97-105

Bentham Science Publishers

Access to resources Recommend Favorite

Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2

By Brubaker Patricia L   Anini Younes  

Canadian Journal of Physiology and Pharmacology, Vol. 81, Iss. 11, 2003-11 ,pp. : 1005-1012

NRC Research Press

Access to resources Recommend Favorite